固形腫瘍におけるDNAミスマッチ修復欠損の同定のための4つのモノヌクレオチドリピートマーカーの正確性 by Takehara, Yuko
Takehara et al. J Transl Med  (2018) 16:5 
https://doi.org/10.1186/s12967-017-1376-4
RESEARCH
Accuracy of four mononucleotide-repeat 
markers for the identification of DNA 
mismatch-repair deficiency in solid tumors
Yuko Takehara1, Takeshi Nagasaka2* , Akihiro Nyuya2, Tomoko Haruma3, Junko Haraga3, Yoshiko Mori1, 
Keiichiro Nakamura3, Toshiyoshi Fujiwara1, C. Richard Boland4 and Ajay Goel4*
Abstract 
Background: To screen tumors with microsatellite instability (MSI) arising due to DNA mismatch repair deficiency 
(dMMR), a panel of five quasi-monomorphic mononucleotide-repeat markers amplified in a multiplex PCR (Pentaplex) 
are commonly used. In spite of its several strengths, the pentaplex assay is not robust at detecting the loss of MSH6-
deficiency (dMSH6). In order to overcome this challenge, we designed this study to develop and optimize a panel 
of four quasi-monomorphic mononucleotide-repeat markers (Tetraplex) for identifying solid tumors with dMMR, 
especially dMSH6.
Methods: To improve the sensitivity for tumors with dMMR, we established a quasi-monomorphic variant range 
(QMVR) of 3–4 bp for the four Tetraplex markers. Thereafter, to confirm the accuracy of this assay, we examined 317 
colorectal cancer (CRC) specimens, comprising of 105 dMMR [45 MutL homolog (MLH)1-deficient, 45 MutS protein 
homolog (MSH)2-deficient, and 15 MSH6-deficient tumors] and 212 MMR-proficient (pMMR) tumors as a test set. In 
addition, we analyzed a cohort of 138 endometrial cancers (EC) by immunohistochemistry to determine MMR protein 
expression and validation of our new MSI assay.
Results: Using the criteria of ≥ 1 unstable markers as MSI-positive tumor, our assay resulted in a sensitivity of 97.1% 
[95% confidence interval (CI) = 91.9–99.0%] for dMMR, and a specificity of 95.3% (95% CI = 91.5–97.4%) for pMMR 
CRC specimens. Among the 138 EC specimens, 41 were dMMR according to immunohistochemistry. Herein, our Tetra-
plex assay detected dMMR tumors with a sensitivity of 92.7% (95% CI = 80.6–97.5%) and a specificity of 97.9% (95% 
CI = 92.8–99.4%) for pMMR tumors. With respect to tumors with dMSH6, in the CRC-validation set, Tetraplex detected 
dMSH6 tumors with a sensitivity of 86.7% (13 of 15 dMSH6 CRCs), which was subsequently validated in the EC test set 
as well (sensitivity, 75.0%; 6 of 8 dMSH6 ECs).
Conclusions: Our newly optimized Tetraplex system will help offer a robust and highly sensitive assay for the identifi-
cation of dMMR in solid tumors.
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Background
Microsatellite instability (MSI) is characterized by 
the accumulation of insertion-deletion mutations at 
microsatellite-repeat sequences and represents a hall-
mark feature of cancer cells with DNA mismatch-repair 
deficiency (dMMR) [1, 2]. Inactivation of any one or a 
combination of MMR genes, including MutL homolog 
(MLH)1, MutS protein homolog (MSH)2, MSH6, and 
PMS2, can result in MSI. Originally, MSI was discov-
ered to correlate with germline defects in MMR genes in 
patients with Lynch syndrome, where > 90% of colorec-
tal cancer (CRC) patients exhibit this phenotype [3, 4]. 
It was later recognized that MSI also occurs in ~  12 to 
~ 15% of sporadic CRCs that lack germline MMR muta-
tions; however, in these patients, MSI manifests due to 
methylation-induced silencing of the MLH1 promoter 
[5, 6]. Determination of MMR deficiency by MSI status 
or immunohistochemical staining for MMR proteins in 
CRC patients has clinical significance due to its prog-
nostic and therapeutic implications [7]. Patients with 
MSI CRCs typically have better prognosis, although 
these cancers are less responsive to 5FU-based adjuvant 
chemotherapy [8]. Recently, clinical trials demonstrated 
the utility of MSI status in predicting response to PD-1 
blockade in advanced unresectable solid tumor patients 
[9–11]. Additionally, MSI status was a significant predic-
tor of the immune-related objective response rate [40% in 
dMMR CRC, 71% in dMMR non-CRC, 0% in MMR-pro-
ficient (pMMR) CRC] and immune-related progression-
free survival rates (78, 67, and 11%, respectively) [9].
The procedures and criteria used to determine MSI in 
tumors are constantly evolving; however, there remains a 
lack of consensus regarding the most practical and robust 
MSI assay allowing for inexpensive clinical use and capa-
ble of providing consistent and reproducible results in 
laboratories worldwide [12]. In an effort to unify MSI 
analysis in CRC patients, in 1997, a National Cancer 
Institute (NCI) workshop recommended the use of a ref-
erence panel of five markers: two mononucleotide-repeat 
markers (BAT26 and BAT25) and three dinucleotide-
repeat markers (D2S123, D5S346, and D17S250) [13]. 
In a follow-up NCI workshop, the panel recognized that 
the original markers had limitations, primarily due to the 
inclusion of the three dinucleotide-repeat markers [14]. 
First, it was noted that the dinucleotide-repeat mark-
ers were more suitable for identifying MSI-low tumors, 
whereas mononucleotide-repeat markers were more spe-
cific and sensitive for the determination of MSI-positive 
CRCs [15]. Second, due to the polymorphic nature of 
dinucleotide markers, these required PCR amplification 
of both the tumor DNA and matching normal specimens 
from each individual in order to interpret the results. 
Third, the conventional NCI-panel markers inadequately 
identified MSH6-deficient CRCs. Employing a panel of 
five quasi-monomorphic mononucleotide-repeat mark-
ers in a pentaplex PCR obviated the need for obtaining 
normal DNA from each CRC patient and offered better 
specificity and sensitivity relative to the NCI-panel mark-
ers [16]. Unfortunately, despite its obvious strengths, the 
pentaplex MSI approach gained limited acceptance for 
MSI-based screening of CRC patients, possibly due to a 
lack of clear understanding of the technical aspects of the 
assay and a paucity of data enabling its validation in inde-
pendent laboratories. To address this concern, we previ-
ously performed a comprehensive determination of the 
accuracy of the pentaplex-panel markers in a large series 
of dMMR and pMMR CRCs by analyzing the PCR-ampli-
fied profiles of each marker in both tumor and matching 
normal DNA [17]. Based on the results of that study, we 
found that a smaller panel of only three markers, BAT26, 
NR21, and NR27, were adequate or better in identifying 
dMMR CRCs as compared with the original panel of five 
mononucleotide markers [17]. However, despite various 
practical and technical strengths of this panel of MSI 
markers for identifying MSI-positive CRCs, one of the 
limitations of these markers was their lack of robustness 
in identifying CRCs exhibiting MSH6-deficiency [17]. 
These data highlighted the need for developing a more 
robust assay capable of addressing this important issue 
and successfully identifying CRCs lacking MSH6.
Therefore, in the present study, we examined a panel of 
four quasi-monomorphic mononucleotide-repeat mark-
ers (BAT26, NR21, NR27, and CAT25) amplified in a sin-
gle multiplex PCR reaction (Tetraplex) to determine its 
performance in detecting dMMR CRCs. This assay was 
first performed in a cohort of 318 CRC specimens, com-
prising 105 dMMR and 213 pMMR cases. Because the 
frequency of MSI tumor is the highest in the endome-
trium [2], we also analyzed the performance of our MSI 
assay in another cohort of 138 specimens with endome-
trial cancer (EC) exhibiting known MMR status.
Methods
CRC specimens in the test cohort
Matched germline and tumor DNA from 212 CRC 
patients diagnosed as pMMR by immunohistochemical 
(IHC) staining were collected from patients at the Okay-
ama University Hospital (Okayama, Japan). Specimens 
from CRC patient with tumors diagnosed as dMMR 
(105) were also collected at three different institutions, 
including: (1) Baylor University Medical Center (Dallas, 
TX, USA); (2) University of Heidelberg (Heidelberg, Ger-
many); and (3) Okayama University Hospital (Okayama, 
Japan). This cohort of 105 dMMR CRC tumors included 
45 MLH1-deficient (dMLH1), 45 MSH2-deficient 
(dMSH2), and 15 MSH6-deficient (dMSH6) tumors. 
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Tumor DNA was extracted from serial sections  (5  μm) 
from the 105 formalin-fixed paraffin-embedded (FFPE) 
tumor tissues. FFPE samples were routinely stained, and 
representative tumor regions were identified for DNA 
extraction by microscopic examination. Genomic DNA 
was isolated from paraffin-embedded tissues using the 
QIAamp DNA mini kit (Qiagen, Valencia, CA). The Insti-
tutional Review Board at each of the three institutions 
granted approval for this study.
EC specimens for the validation cohort
A total of 138 tumor samples were collected from 
EC patients at Okayama University Hospital (Okay-
ama, Japan). Among these, 23 were dMLH1, eight were 
dMSH2, eight were dMSH6, and two were PMS2-
deficient. Tumor DNA was collected and extracted as 
described for the CRC tumors. The Institutional Review 
Board at Okayama University Hospital granted approval 
for this study.
MMR protein IHC
We examined MMR-protein expression for the MLH1, 
MSH2, MSH6, and PMS2 proteins in primary tumors 
from 317 CRC and 138 EC patients by IHC. Thin (5 µm) 
sections of representative blocks were deparaffinized and 
dehydrated using an ethanol gradient. Following antigen 
retrieval in citrate buffer (pH 6.0), endogenous peroxi-
dase was blocked with 3%  H2O2. Thereafter, slides were 
incubated overnight in the presence of purified mouse 
monoclonal antibodies against MLH1 (clone G168-
15; 1:50; BD Pharmingen, San Diego, CA, USA), MSH2 
(clone G219-1129; 1:200; BD Pharmingen), MSH6 (clone 
44/MSH6; 1:100; BD Pharmingen), and PMS2 (clone 
A16-4; 1:200; BD Pharmingen). Additional incubations 
were performed with a biotin-conjugated secondary anti-
body (Vector Laboratories, Burlingame, CA, USA), the 
avidin–biotin–peroxidase complex (Vector Laborato-
ries, Burlingame, CA, USA), and with biotinyl tyramide, 
followed by streptavidin peroxidase. Diaminobenzidine 
was used as a chromogen, and hematoxylin was used as a 
nuclear counterstain. Tumor cells were scored as negative 
for MMR-protein expression only if the epithelial cells 
within the tumor tissue lacked nuclear staining while 
the surrounding stromal cells were positive for MMR 
staining. Tumor tissue with all MMR proteins present 
were defined as pMMR, and those showing deficiency 
in at least one of the four MMR proteins were defined as 
dMMR.
Tetraplex system and quasi‑monomorphic variation range 
(QMVR) definition
MSI analysis was performed using four mononucleotide-
repeat microsatellite targets (CAT25, NR21, NR27, and 
BAT26) in a single multiplex PCR reaction (Tetraplex). 
Primer sequences are shown in Additional file  1: Table 
S1, and each sense primer was end-labeled with one of 
the following fluorescent markers: PET, NED, VIC, or 
6-FAM. PCR conditions for the Tetraplex assay consisted 
of an initial 15-min denaturation step at 95 °C, followed 
by 35 cycles at 95 °C for 30 s, 55 °C for 30 s, and 72 °C for 
30  s, with a final extension at 72  °C for 10  min. Ampli-
fied PCR products were diluted with formamide and sub-
jected to electrophoresis using an Applied Biosystems 
310 Avant automated capillary electrophoresis DNA 
sequencer (Applied Biosystems, Foster City, CA, USA). 
Allelic sizes for each of the markers were determined 
using GeneMapper 3.1 software (Applied Biosystems).
Determination and validation of the QMVR for each 
of the four MSI markers was performed by individually 
scoring PCR-amplification profiles, and the size of both 
alleles was determined for each marker and for each 
tumor individually as described previously [17, 18].
Statistical analyses
We used logistic regression analysis to examine the diag-
nostic performance of measuring MMR status in CRCs 
by utilizing different strategies to define MSI. Analyses 
were performed using JMP (v10.0.2; SAS Institute, Cary, 
NC, USA).
Results
Determination of QMVR for each marker by germline DNA
Mono-nucleotide repeat markers are highly monomor-
phic in germline DNA from a wide spectrum of popula-
tions worldwide [18]. Theoretically, the QMVR for each 
marker should be constant in each experimental setting; 
however, results indicate that specific instrumentation or 
reagents might affect allele-size measurements for each 
marker [18]. This requires a one-time careful validation of 
QMVR in germline DNA prior to analysis of tumor MSI. 
We amplified matching germline DNA and tumor DNA 
from 212 CRC patients with pMMR tumors based on 
IHC staining in order to determine the QMVR for each 
MSI marker. Figure 1 shows the QMVR and sifted size of 
dMMR cases for each marker in the test set. The poly-
morphic range for each mononucleotide-repeat marker 
in germline DNA was as follows: CAT25 (106–108  bp), 
NR21 (131–134  bp), NR27 (153–156  bp), and BAT26 
(175–177  bp). The most common allele for each of the 
markers was as follows: CAT25 (108 bp), NR21 (133 bp), 
NR27 (154  bp), and BAT26 (176  bp). As a comparison, 
the theoretical size of each marker is shown in Additional 
file  1: Table S1: CAT25 (109  bp), NR21 (133  bp), NR27 
(159 bp), and BAT26 (182 bp) (a MSI case determined by 
Tetlaplex PCR assay is shown in Additional file 2: Figure 
S1). These results indicated that our amplification system 
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reported the most common alleles as being shorter than 
the theoretical size for each marker (CAT25 by 1  bp, 
NR21 by 0 bp, NR27 by 5 bp, and BAT26 by 6 bp).
Performance characteristics of Individual Allelic Markers 
for the identification of MMR‑deficient CRCs in the test set
We examined the performance characteristics of indi-
vidual markers for identifying CRCs with dMMR 
(Table  1). Our analysis clearly showed that all four 
mononucleotide-repeat markers were able to detect 
dMMR CRCs with a sensitivity that varied from 91.4% 
(NR21) to 95.2% (BAT26) and a specificity for pMMR 
CRCs from 97.6% (NR27) to 100% (CAT25). The high-
est sensitivity was observed with dMSH2 tumors, 
whereas the lowest sensitivity was observed with 
dMSH6 tumors.
Performance of the Tetraplex system for identification 
of dMMR tumors in the test set
We then examined the ability of the combination of all 
four allelic markers to determine dMMR or pMMR in 
CRCs using the Tetraplex system. When allelic-size var-
iations at ≥  1 of the four markers was defined as diag-
nosis of MSI, the Tetraplex system displayed 97.1% 
(95% confidence interval [CI]  =  91.9–99.0%] sensitiv-
ity for identification of dMMR CRCs and 95.3% (95% 
CI = 91.5–97.4%) specificity for pMMR CRCs (Table 2).
With respect to correlation of MSI data with MMR-
protein-expression status, the Tetraplex system dem-
onstrated a very high sensitivity for dMLH1 (100%) and 
dMSH2 tumors (100%). Additionally, this system was suf-
ficiently robust for the detection of dMSH6 tumors with 
a sensitivity of 86.7% (13 of 15) when MSI was defined as 
instability at ≥ 1 of four markers (Fig. 2).
Profiles of the MMR‑expression Status of ECs and QMVR 
distribution for each marker in the validation set
To determine the ability of the Tetraplex system to detect 
dMMR tumors in other types of cancer, we performed 
similar analyses on EC specimens. We first examined the 
expression status of MMR proteins in a cohort of 138 
ECs. IHC staining confirmed 41 ECs (29.7%) as dMMR: 
23 ECs with dMLH1 (56.1% of ECs with dMMR), eight 
with dMSH2 (19.5%), eight with dMSH6 (19.5%), and 
two with PMS2 deficiency (4.9%). We then amplified the 
four allelic markers used for CRC and determined the 
distribution of QMVR and size-sorted alleles within each 
dMMR type. As shown in Fig. 3, there was a clear shift to 
(See figure on previous page.) 
Fig. 1 Frequency of allele-size distribution (in base pairs) for the four individual markers in the test set. Allele-size distribution from 212 pMMR 
tumors and their corresponding normal mucosa, 45 dMLH1, 45 dMSH2, and 15 dMSH6 tumors. For each marker, gray shading indicates the 
adjusted QMVR
Table 1 Performance characteristics of each MSI marker for the identification of MMR-deficient CRCs in the test set (317 
CRCs)
PPV positive predictive value, NPV negative predictive value
Marker References Sensitivity% (95% CI) Specificity% (95% CI) 
for pMMR
PPV% (95% CI) for dMMR NPV% (95% CI) for pMMR
CAT25 QMVR
(106–108 bp)
for dMMR (n = 105) 94.3 (88.1–97.4) 100.0 (98.2–100) 100 (96.3–100) 97.3 (94.1–98.7)
dMLH1 (n = 45) 93.3 (82.1–97.7)
dMSH2 (n = 45) 100 (92.1–100)
dMSH6 (n = 15) 80.0 (54.8–93.0)
NR21 QMVR
(131–134 bp)
for dMMR (n = 105) 91.4 (84.5–95.4) 99.5 (97.4–99.9) 99.0 (94.3–99.8) 95.9 (92.4–97.8)
dMLH1 (n = 45) 95.6 (85.2–98.8)
dMSH2 (n = 45) 97.8 (88.4–99.6)
dMSH6 (n = 15) 60.0 (35.7–80.2)
NR27 QMVR
(153–156 bp)
for dMMR (n = 105) 94.3 (88.1–97.4) 97.6 (94.6–99.0) 95.2 (89.2–97.9) 97.2 (94.0–98.7)
dMLH1 (n = 45) 95.6 (85.2–98.8)
dMSH2 (n = 45) 100 (92.1–100)
dMSH6 (n = 15) 73.3 (48.0–89.1)
BAT26 QMVR
(175–177 bp)
for dMMR (n = 105) 95.2 (89.3–97.9) 98.1 (95.2–99.3) 96.2 (90.5–98.5) 97.7 (94.6–99.0)
dMLH1 (n = 45) 97.8 (88.4–99.6)
dMSH2 (n = 45) 100 (92.1–100)
dMSH6 (n = 15) 73.3 (48.0–89.1)
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smaller allele size in dMMR samples as compared to that 
observed in pMMR samples.
Performance characteristics of Individual Allelic Markers 
for the identification of MMR‑deficient ECs in the 
validation set
We then examined the performance characteristics of 
individual markers for identifying dMMR ECs (Table 3). 
Our analysis clearly showed the ability of the four mon-
onucleotide-repeat markers to detect dMMR ECs. The 
sensitivity for dMMR in the different alleles varied from 
78.1 to 90.2%, and the specificity for pMMR ECs was 
from 99.0 to 100%.
Performance of the Tetraplex system for identification 
of dMMR tumors in the EC validation set
We examined the performance of all markers using the 
Tetraplex system in both dMMR and pMMR ECs. With 
allelic-size variations at ≥ 1 of the four markers defined 
as diagnosis of MSI, the Tetraplex system displayed 92.7% 
(95% CI  =  80.6–97.5%) sensitivity for identification of 
dMMR ECs and 97.9% (95% CI = 92.8–99.4%) specificity 
for pMMR ECs (Table 4).
The correlation of MSI data with MMR-protein-
expression status demonstrated a sensitivity for dMLH1 
(95.7%), dMSH2 (100%), dMSH6 (75.0%), and PMS2-
deficient (100%) tumors using the Tetraplex system 
(Fig. 4).
Table 2 Performance characteristics of Tetraplex system with reference to QMVR for identification of MMR-deficient CRCs 
in the test set
Results are expressed as percentages (%), with 95% confidence intervals in parentheses
PPV positive predictive value, NPV negative predictive value
No. of markers displaying allelic variation The Tetraplex marker panel
Sensitivity (%) Specificity (%) PPV (%) NPV (%)
4 88.6 (81.1–93.3) 100 (98.2–100) 100 (96.0–100) 94.6 (90.9–96.9)
3 95.2 (89.3–97.9) 100 (98.2–100) 100 (96.3–100) 97.7 (94.7–99.0)
2 96.2 (90.6–98.5) 100 (98.2–100) 100 (96.4–100) 98.1 (95.3–99.3)
1 97.1 (91.9–99.0) 95.3 (91.5–97.4) 91.1 (84.3–95.1) 98.6 (95.8–99.5)
Fig. 2 The performance of the Tetraplex system in the test set. A colored circle denotes a positive for allelic variation (or MSI), and an empty circle 
indicates a negative for variation (or microsatellite stable) in this specific allele
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Discussion
Colorectal cancer (CRC) is believed to initiate as a benign 
adenomatous polyp, which subsequently develops into an 
advanced adenoma with high-grade dysplasia, and finally 
progresses to an invasive cancer. The clinical challenge 
remains a better understanding of the molecular basis 
of an individual’s susceptibility for developing CRC, and 
to determine factors that initiate development of tumor, 
drive its progression, and determine its responsiveness to 
antitumor agents. By Through the efforts of The Cancer 
Genome Atlas (TCGA), CRCs can now at least be clas-
sified into the two clusters; a hypermutator and a non-
hypermutator phenotype [19, 20]. The hypermutated 
CRCs are also categorized into the following two subsets; 
Table 3 Performance characteristics of each MSI marker for the identification of MMR-deficient ECs in validation test set 
(n = 138)
PPV, positive predictive value, NPV negative predictive value
Marker References Sensitivity% (95% CI) Specificity% (95% CI) 
for pMMR
PPV% (95%CI) for  
dMMR
NPV% (95% CI) for  
pMMR
CAT25 QMVR
(106–108 bp)
for dMMR (n = 41) 80.5 (66.0–89.8) 100 (96.2–100) 100 (89.6–100) 92.4 (85.7–96.1)
dMLH1 (n = 23) 82.6 (62.9–93.0)
dMSH2 (n = 8) 100 (67.5–100)
dMSH6 (n = 8) 50.0 (21.5–78.5)
dPMS2 (n = 2) 100 (34.2–100)
NR21 QMVR
(131–134 bp)
for dMMR (n = 41) 78.1 (63.3–88.0) 99.0 (94.4–99.8) 97.0 (84.7–99.5) 91.4 (84.5–95.4)
dMLH1 (n = 23) 69.6 (49.1–84.4)
dMSH2 (n = 8) 100 (67.5–100)
dMSH6 (n = 8) 62.5 (30.6–86.3)
dPMS2 (n = 2) 100 (34.2–100)
NR27 QMVR
(153–156 bp)
for dMMR (n = 41) 90.2 (77.5–96.1) 99.0 (94.4–99.8) 97.4 (86.5–99.5) 96.0 (90.2–98.4)
dMLH1 (n = 23) 95.7 (79.0–99.2)
dMSH2 (n = 8) 100 (67.5–100)
dMSH6 (n = 8) 62.5 (30.6–86.3)
dPMS2 (n = 2) 100 (34.2–100)
BAT26 QMVR
(175–177 bp)
for dMMR (n = 39) 87.8 (74.5–94.7) 100 (96.2–100) 100 (90.4–100) 95.1 (89.0–97.9)
dMLH1 (n = 23) 91.3 (73.2–97.6)
dMSH2 (n = 8) 100 (67.5–100)
dMSH6 (n = 8) 62.5 (30.6–86.3)
dPMS2 (n = 2) 100 (34.2–100)
Table 4 Performance characteristics of Tetraplex system with reference to QMVR for identification of MMR-deficient ECs 
in the validation set (n = 138)
Results are expressed as percentages (%), with 95% confidence intervals in parentheses
PPV positive predictive value, NPV negative predictive value
No. of markers displaying  
allelic variation
The Tetraplex marker panel
Sensitivity (%)　 Specificity (%) PPV (%) NPV (%)
4 70.7 (55.5–82.4) 100 (96.2–100) 100 (88.3–100) 89.0 (81.7–93.6)
3 85.4 (71.6–93.1) 100 (96.2–100) 100 (90.1–100) 94.2 (87.9–97.3)
2 87.8 (74.5–94.7) 100 (96.2–100) 100 (90.4–100) 95.1 (89.0–97.9)
1 92.7 (80.6–97.5) 97.9 (92.8–99.4) 95.0 (83.5–98.6) 96.9 (91.4–99.0)
(See figure on previous page.) 
Fig. 3 Frequency of allele-size distribution (in base pairs) for the four individual markers in the validation set. Allele-size distribution from 97 pMMR 
ECs: 23 dMLH1, eight dMSH2, eight dMSH6, and two PMS2-deficient ECs. For each marker, gray shading indicates the adjusted QMVR
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tumors lacking DNA repair due to the mutations in the 
exonuclease domain of DNA polymerase E (POLE) char-
acterized by an ultramutator phenotype, and a larger pro-
portion of tumors with DNA mismatch repair deficiency 
(dMMR) and ensuing microsatellite instability (MSI) 
phenotype. This alterations in the POLE gene are distinct 
from the better-known dMMR which results in the clas-
sic MSI phenotype [20].
Recently, several studies have demonstrated that MSI 
is a positive predictor for immune-checkpoint blockade 
[9–11]. Hence, MSI analysis is now becoming important 
not only for the screening of Lynch Syndrome patients, 
but has a much larger role in identifying tumors exhibit-
ing such a hypermutator phenotype that might respond 
to immune-checkpoint drugs. This includes analysis 
of sporadic as well as hereditary cases, of cancers with 
defects in the MMR system. The availability of a robust 
MSI assay that is fast, cost-efficient, and highly accu-
rate for identifying dMMR in solid tumors is critical for 
its successful application in the clinic and research. In 
this study, we describe the development and application 
of a rapid and accurate MSI assay, which uses a single 
PCR reaction for the amplification of four mononucleo-
tide microsatellite markers. This assay was subsequently 
validated for its usefulness in identifying MSI status in a 
series of pMMR and dMMR CRCs, as well as in ECs.
Standard MSI analysis using an NCI panel consist-
ing of five microsatellite markers (two mononucleotide 
and three dinucleotide repeats) remains the preferred 
method in most clinical and research laboratories [14]. 
This is unfortunate, given that multiple studies have 
repeatedly shown that dinucleotide repeats are better 
suited to detecting MSI-low tumors, of which most are 
pMMR [14, 15], whereas mononucleotide MSI markers 
offer higher accuracy for detecting dMMR tumors [16].
We previously illustrated the usefulness of a pentaplex 
PCR system consisting of five mononucleotide markers, 
BAT25, BAT26, NR21, NR24, and NR27 [17]. A pair-
wise correlation and hierarchical-clustering analysis in 
this study clearly showed the weakest predictive values 
associated with NR24 and BAT25 as compared to the 
remaining three markers (BAT26, NR21, and NR27). Our 
observation of high sensitivity and positive predictive 
value with the reduced panel of three markers (BAT26, 
NR21, and NR27) versus the use of a panel consisting of 
all five markers has economic implications for MSI-based 
assays, as the use of this smaller marker panel might 
result in lower CRC-screening costs in the future [17]. 
One of the limitations of the NCI-panel markers is their 
inability to identify dMSH6 CRCs. Unfortunately, our 
previous study indicated that, even with the use of mono-
markers in the pentaplex panel, the sensitivity of the assay 
to detect dMSH6 CRCs remained relatively low relative 
to dMMR due to the loss of other MMR proteins in CRCs 
[17]. This is significant, because the MutSα, a heterodi-
meric complex consisting of MSH2 and MSH6, preferen-
tially recognizes base/base mismatches, as well as small 
insertion/deletion loops, containing one or two unpaired 
nucleotides in the DNA sequence, a subsequently par-
ticipates in the repair of these lesions [21]. Therefore, 
one would expect that the functional loss of MutSα due 
to dMSH6 would lead to preferential instability in loci 
Fig. 4 The performance of the Tetraplex system on the validation set. A colored circle denotes a positive for allelic variation (or MSI), and an empty 
circle indicates a negative for variation (or microsatellite stable) in this specific allele
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containing mononucleotide repeats [22]. Therefore, in 
this study, we included another mononucleotide marker, 
CAT25, to improve the sensitivity of our assay for identi-
fying dMSH6 tumors [23]. In the CRC-validation set, our 
new four-marker panel detected dMSH6 tumors with a 
sensitivity of 86.7% (13 of 15 dMSH6 CRCs). This level 
of accuracy was also observed in the EC test set, where 
the system detected dMSH6 tumors with a sensitivity of 
75.0% (6 of 8 dMSH6 ECs).
During the development of an assay exhibiting higher 
sensitivity for dMMR tumors, we considered that the 
most important factor for developing a more sensitive 
MSH6 marker would be the QMVR range. Indeed, the 
normal QMVR for the four markers used in this study 
was three to four bp. This robust range of QMVRs might 
improve the sensitivity for dMMR tumors, especially 
dMSH6 tumors. With regards to potential limitations, 
in our study the test set did not include any PMS2-defi-
cient tumors. In addition, the sensitivity of this assay for 
detecting MSH6-deficiency is still under 90% in the both 
test and validation set.
Conclusion
We describe a novel optimized PCR-based assay for 
screening MSI-positive solid tumors. This Tetraplex assay 
represents a simple and rapid screening approach with 
high-throughput capability, does not require amplifica-
tion of matched normal DNA from a cancer patient, and 
exhibits a high degree of sensitivity and specificity for the 
detection of dMMR in ECs, as well as CRCs. We propose 
that this assay will help replace existing methodologies 
to aid in the improvement of detection of tumors with 
dMMR.
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